Nasal spray could tame racing heart in AFib patients

NCT ID NCT06716021

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an investigational nasal spray called etripamil for people with atrial fibrillation (AFib) who experience episodes of dangerously fast heart rate. About 750 adults will be randomly assigned to use either the real spray or a placebo at home when symptoms start. The goal is to see if the spray can quickly lower heart rate within 30 minutes, potentially offering a convenient way to manage sudden episodes without a trip to the hospital.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.